Bukatina_1991_Zh.Nevropatol.Psikhiatr.Im.S.S.Korsakova_91_53

As many as 88 patients with Alzheimer's type senile dementia were followed up. Of these, 28 patients suffered from marked and 60 from unpronounced dementia. 74 patients received amiridine and 14 made up a control group. Amiridine was administered per os in the daily doses 20, 40 and 60 mg. The treatment lasted up to 14 months. The follow-up studies included clinical observations and testing according to a specially devised scale. A double blind study was carried out together with examinations of the drug withdrawal effect and comparisons of the main and control groups. All the tests demonstrated amiridine to have a well-defined therapeutic effect in 30-46% of the patients. Cognitive functions and the general mental status of the patients continued improving or got stabilized for a long time (up to 14 months). The speech improved for a shorter period of time. Amiridine was found to produce a beneficial effect both at the initial and marked stages of the disease. The most significant results were attained in the patients with unmarked dementia. The treatment efficacy correlated well with the dose of amiridine.